+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
New

Critical Limb Ischemia Treatment - Global Strategic Business Report

  • PDF Icon

    Report

  • 375 Pages
  • April 2025
  • Region: Global
  • Global Industry Analysts, Inc
  • ID: 6070426
The global market for Critical Limb Ischemia Treatment was estimated at US$5.6 Billion in 2024 and is projected to reach US$8.1 Billion by 2030, growing at a CAGR of 6.5% from 2024 to 2030. This comprehensive report provides an in-depth analysis of market trends, drivers, and forecasts, helping you make informed business decisions. The report includes the most recent global tariff developments and how they impact the Critical Limb Ischemia Treatment market.

Global Critical Limb Ischemia Treatment Market - Key Trends & Drivers Summarized

Why Is the Demand for Critical Limb Ischemia Treatment Increasing? Understanding the Rise in Peripheral Artery Disease Cases

The global critical limb ischemia (CLI) treatment market is witnessing rapid growth due to the increasing prevalence of peripheral artery disease (PAD), diabetes, and cardiovascular conditions. CLI is a severe form of PAD that leads to reduced blood flow in the lower extremities, often resulting in non-healing ulcers, gangrene, and amputation risks. As the global burden of chronic diseases rises, healthcare providers and pharmaceutical companies are focusing on advanced treatment options to improve patient outcomes. Aging populations, lifestyle-related risk factors, and the growing incidence of obesity have further fueled the demand for effective CLI therapies. Additionally, advancements in minimally invasive endovascular procedures and regenerative medicine have provided new hope for CLI patients.

What Are the Leading Treatment Options for Critical Limb Ischemia? Exploring Key Segments

The CLI treatment market consists of various therapeutic approaches, including revascularization procedures, pharmacological interventions, and emerging regenerative therapies. Endovascular treatments, such as angioplasty and stent placement, remain the gold standard for restoring blood flow in CLI patients, with newer drug-coated balloon technologies enhancing long-term efficacy. Surgical interventions, including bypass grafting, are also widely used for severe cases. Pharmacological treatments, including antiplatelet and anticoagulant therapies, play a critical role in preventing disease progression. Additionally, regenerative medicine approaches, such as stem cell therapy and gene-based treatments, have shown promising results in promoting vascular regeneration and wound healing. The integration of telemedicine and AI-driven diagnostics is further improving early detection and personalized treatment strategies.

How Is Technology Transforming CLI Treatment? The Role of AI, Biomaterials & Personalized Medicine

The field of CLI treatment is evolving with technological innovations in biomaterials, AI-driven diagnostics, and precision medicine. AI-powered imaging tools are enhancing early detection by analyzing vascular health and identifying ischemic regions with greater accuracy. The development of bioengineered vascular grafts and tissue scaffolds has improved treatment outcomes by providing long-lasting blood flow restoration. Additionally, advances in gene therapy and stem cell transplantation are offering potential regenerative solutions, reducing the need for amputation. Wearable health monitoring devices are also playing a role in tracking blood circulation, enabling real-time patient management. As personalized medicine gains traction, tailored therapeutic strategies based on genetic and metabolic profiles are improving CLI treatment efficacy.

What’s Driving the Growth of the CLI Treatment Market? Key Market Influencers Explained

The growth in the critical limb ischemia treatment market is driven by increasing disease prevalence, rising healthcare expenditures, and advancements in endovascular and regenerative therapies. The expansion of vascular surgery and interventional cardiology programs has improved access to advanced CLI treatments. Additionally, government initiatives promoting early screening and PAD awareness have contributed to higher diagnosis rates. The rise of value-based healthcare models has encouraged the development of cost-effective CLI therapies, making treatment more accessible to underserved populations. With continued research in novel vascular regeneration techniques and expanding global healthcare infrastructure, the CLI treatment market is poised for significant advancements and long-term growth.

Report Scope

The report analyzes the Critical Limb Ischemia Treatment market, presented in terms of market value (US$ Thousand). The analysis covers the key segments and geographic regions outlined below.

Segments: DFU Treatment (Wound Care Dressings, Biologics, Therapy Devices, Antibiotic Medications, Other DFU Treatments); DFU Treatment Ulcer Type (Neuropathic Ulcers, Ischemic Ulcers, Neuro-ischemic Ulcers); DFU Treatment End-Use (Hospital End-Use, Ambulatory Surgery Centre End-Use, Other End-Uses)

Geographic Regions/Countries: World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; Spain; Russia; and Rest of Europe); Asia-Pacific (Australia; India; South Korea; and Rest of Asia-Pacific); Latin America (Argentina; Brazil; Mexico; and Rest of Latin America); Middle East (Iran; Israel; Saudi Arabia; United Arab Emirates; and Rest of Middle East); and Africa.

Key Insights:

  • Market Growth: Understand the significant growth trajectory of the Wound Care Dressings segment, which is expected to reach US$2.8 Billion by 2030 with a CAGR of a 4.8%. The Biologics segment is also set to grow at 8.2% CAGR over the analysis period.
  • Regional Analysis: Gain insights into the U.S. market, estimated at $1.5 Billion in 2024, and China, forecasted to grow at an impressive 9.8% CAGR to reach $1.6 Billion by 2030. Discover growth trends in other key regions, including Japan, Canada, Germany, and the Asia-Pacific.

Why You Should Buy This Report:

  • Detailed Market Analysis: Access a thorough analysis of the Global Critical Limb Ischemia Treatment Market, covering all major geographic regions and market segments.
  • Competitive Insights: Get an overview of the competitive landscape, including the market presence of major players across different geographies.
  • Future Trends and Drivers: Understand the key trends and drivers shaping the future of the Global Critical Limb Ischemia Treatment Market.
  • Actionable Insights: Benefit from actionable insights that can help you identify new revenue opportunities and make strategic business decisions.

Key Questions Answered:

  • How is the Global Critical Limb Ischemia Treatment Market expected to evolve by 2030?
  • What are the main drivers and restraints affecting the market?
  • Which market segments will grow the most over the forecast period?
  • How will market shares for different regions and segments change by 2030?
  • Who are the leading players in the market, and what are their prospects?

Report Features:

  • Comprehensive Market Data: Independent analysis of annual sales and market forecasts in US$ Million from 2024 to 2030.
  • In-Depth Regional Analysis: Detailed insights into key markets, including the U.S., China, Japan, Canada, Europe, Asia-Pacific, Latin America, Middle East, and Africa.
  • Company Profiles: Coverage of players such as Abbott Laboratories, AnGes, Inc., B. Braun Melsungen AG, Bayer AG, Boston Scientific Corporation and more.
  • Complimentary Updates: Receive free report updates for one year to keep you informed of the latest market developments.

Select Competitors (Total 36 Featured):

  • Abbott Laboratories
  • AnGes, Inc.
  • B. Braun Melsungen AG
  • Bayer AG
  • Boston Scientific Corporation
  • Cardiovascular Systems, Inc.
  • Cesca Therapeutics (ThermoGenesis Holdings, Inc)
  • Cook Medical
  • Cynata Therapeutics Ltd
  • Eli Lilly and Company
  • LimFlow SA
  • Medtronic plc
  • Micro Medical Solutions
  • Mitsubishi Tanabe Pharma Corporation
  • Pfizer Inc.
  • Pluristem Therapeutics Inc.
  • Rexgenero Ltd.
  • Sanofi
  • Terumo Corporation
  • Teva Pharmaceuticals

Tariff Impact Analysis: Key Insights for 2025

Global tariff negotiations across 180+ countries are reshaping supply chains, costs, and competitiveness. This report reflects the latest developments as of April 2025 and incorporates forward-looking insights into the market outlook.

The analysts continuously track trade developments worldwide, drawing insights from leading global economists and over 200 industry and policy institutions, including think tanks, trade organizations, and national economic advisory bodies. This intelligence is integrated into forecasting models to provide timely, data-driven analysis of emerging risks and opportunities.

What’s Included in This Edition:

  • Tariff-adjusted market forecasts by region and segment
  • Analysis of cost and supply chain implications by sourcing and trade exposure
  • Strategic insights into geographic shifts

Buyers receive a free July 2025 update with:

  • Finalized tariff impacts and new trade agreement effects
  • Updated projections reflecting global sourcing and cost shifts
  • Expanded country-specific coverage across the industry

Table of Contents

I. METHODOLOGYII. EXECUTIVE SUMMARY
1. MARKET OVERVIEW
  • Influencer Market Insights
  • Tariff Impact on Global Supply Chain Patterns
  • Critical Limb Ischemia Treatment - Global Key Competitors Percentage Market Share in 2024 (E)
  • Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2024 (E)
2. FOCUS ON SELECT PLAYERS
3. MARKET TRENDS & DRIVERS
  • Increasing Prevalence of Peripheral Arterial Disease (PAD) and Diabetes Drives Growth in Critical Limb Ischemia Treatment Demand
  • Rising Aging Population and Associated Vascular Diseases Expands Market Opportunity for CLI Treatment Solutions
  • Advancements in Endovascular Procedures Strengthen the Business Case for Minimally Invasive CLI Treatment Options
  • Surge in Smokers and Obesity Rates Expands Addressable Market for Critical Limb Ischemia Therapies
  • Increasing Focus on Early Detection and Prevention Strategies Propels Growth in CLI Treatment and Management Tools
  • Technological Innovations in Angioplasty and Stenting Devices Enhance Treatment Outcomes and Drive Adoption of CLI Therapies
  • Growing Adoption of Hybrid Surgical Procedures in CLI Treatment Spurs Demand for Advanced Vascular Interventions
  • Rising Demand for Personalized Medicine and Tailored Treatment Plans Accelerates Market Growth for CLI Therapies
  • Surge in Health Insurance Coverage and Healthcare Accessibility Expands the Market for CLI Treatment Solutions in Emerging Economies
  • Integration of Artificial Intelligence and Imaging Technologies in CLI Diagnosis and Treatment Drives Market Innovation
  • Increasing Use of Stem Cell and Regenerative Medicine Technologies in CLI Treatment Generates New Growth Opportunities
  • Rise in Healthcare Spending and Investment in Specialized Vascular Care Expands the Market for CLI Interventions
  • Growing Focus on Post-Surgery Recovery and Rehabilitation Drives Demand for CLI Treatment Solutions with Shorter Recovery Times
  • Regulatory Changes and Advancements in Clinical Guidelines for CLI Treatment Spur Market Adoption of New Therapeutic Options
  • The Emergence of Telemedicine and Remote Monitoring Solutions Expands Market Opportunity for Post-Treatment CLI Care
  • Rising Awareness of CLI and Vascular Health Challenges Accelerates Demand for Educational Campaigns and Screening Programs
  • Increasing Number of Clinical Trials and Research Projects on CLI Treatment Drives Innovation in Therapies and Technologies
  • Growing Emphasis on Non-Surgical Treatment Options Strengthens Demand for Drug Therapies and Endovenous Laser Therapies for CLI
  • Surge in Peripheral Endovascular Interventions for CLI Treatment Generates Opportunities for Cross-Specialty Collaboration in Healthcare
  • Focus on Minimizing Amputation Rates and Improving Limb Salvage Drives Adoption of Advanced CLI Treatment Modalities
4. GLOBAL MARKET PERSPECTIVE
  • TABLE 1: World Critical Limb Ischemia Treatment Market Analysis of Annual Sales in US$ Million for Years 2015 through 2030
  • TABLE 2: World Recent Past, Current & Future Analysis for Critical Limb Ischemia Treatment by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 3: World Historic Review for Critical Limb Ischemia Treatment by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 4: World 15-Year Perspective for Critical Limb Ischemia Treatment by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets for Years 2015, 2025 & 2030
  • TABLE 5: World Recent Past, Current & Future Analysis for Wound Care Dressings by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 6: World Historic Review for Wound Care Dressings by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 7: World 15-Year Perspective for Wound Care Dressings by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 8: World Recent Past, Current & Future Analysis for Biologics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 9: World Historic Review for Biologics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 10: World 15-Year Perspective for Biologics by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 11: World Recent Past, Current & Future Analysis for Therapy Devices by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 12: World Historic Review for Therapy Devices by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 13: World 15-Year Perspective for Therapy Devices by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 14: World Recent Past, Current & Future Analysis for Antibiotic Medications by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 15: World Historic Review for Antibiotic Medications by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 16: World 15-Year Perspective for Antibiotic Medications by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 17: World Recent Past, Current & Future Analysis for Other DFU Treatments by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 18: World Historic Review for Other DFU Treatments by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 19: World 15-Year Perspective for Other DFU Treatments by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 20: World Recent Past, Current & Future Analysis for Ambulatory Surgery Centre End-Use by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 21: World Historic Review for Ambulatory Surgery Centre End-Use by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 22: World 15-Year Perspective for Ambulatory Surgery Centre End-Use by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 23: World Recent Past, Current & Future Analysis for Other End-Uses by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 24: World Historic Review for Other End-Uses by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 25: World 15-Year Perspective for Other End-Uses by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 26: World Recent Past, Current & Future Analysis for Hospital End-Use by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 27: World Historic Review for Hospital End-Use by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 28: World 15-Year Perspective for Hospital End-Use by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 29: World Recent Past, Current & Future Analysis for Neuropathic Ulcers by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 30: World Historic Review for Neuropathic Ulcers by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 31: World 15-Year Perspective for Neuropathic Ulcers by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 32: World Recent Past, Current & Future Analysis for Ischemic Ulcers by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 33: World Historic Review for Ischemic Ulcers by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 34: World 15-Year Perspective for Ischemic Ulcers by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 35: World Recent Past, Current & Future Analysis for Neuro-ischemic Ulcers by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 36: World Historic Review for Neuro-ischemic Ulcers by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 37: World 15-Year Perspective for Neuro-ischemic Ulcers by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
III. MARKET ANALYSIS
  • UNITED STATES
  • Critical Limb Ischemia Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2025 (E)
  • CANADA
  • JAPAN
  • Critical Limb Ischemia Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2025 (E)
  • CHINA
  • Critical Limb Ischemia Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2025 (E)
  • EUROPE
  • Critical Limb Ischemia Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2025 (E)
  • FRANCE
  • Critical Limb Ischemia Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2025 (E)
  • GERMANY
  • Critical Limb Ischemia Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2025 (E)
  • ITALY
  • UNITED KINGDOM
  • Critical Limb Ischemia Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2025 (E)
  • SPAIN
  • RUSSIA
  • REST OF EUROPE
  • ASIA-PACIFIC
  • Critical Limb Ischemia Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2025 (E)
  • AUSTRALIA
  • Critical Limb Ischemia Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Australia for 2025 (E)
  • INDIA
  • Critical Limb Ischemia Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in India for 2025 (E)
  • SOUTH KOREA
  • REST OF ASIA-PACIFIC
  • LATIN AMERICA
  • Critical Limb Ischemia Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Latin America for 2025 (E)
  • ARGENTINA
  • BRAZIL
  • MEXICO
  • REST OF LATIN AMERICA
  • MIDDLE EAST
  • Critical Limb Ischemia Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Middle East for 2025 (E)
  • IRAN
  • ISRAEL
  • SAUDI ARABIA
  • UNITED ARAB EMIRATES
  • REST OF MIDDLE EAST
  • AFRICA
  • Critical Limb Ischemia Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Africa for 2025 (E)
IV. COMPETITION

Companies Mentioned (Partial List)

A selection of companies mentioned in this report includes, but is not limited to:

  • Abbott Laboratories
  • AnGes, Inc.
  • B. Braun Melsungen AG
  • Bayer AG
  • Boston Scientific Corporation
  • Cardiovascular Systems, Inc.
  • Cesca Therapeutics (ThermoGenesis Holdings, Inc)
  • Cook Medical
  • Cynata Therapeutics Ltd
  • Eli Lilly and Company
  • LimFlow SA
  • Medtronic plc
  • Micro Medical Solutions
  • Mitsubishi Tanabe Pharma Corporation
  • Pfizer Inc.
  • Pluristem Therapeutics Inc.
  • Rexgenero Ltd.
  • Sanofi
  • Terumo Corporation
  • Teva Pharmaceuticals

Table Information